Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

GSK PLC closed 18.99% short of its 52-week high of £17.88, which the company achieved on May 28th.

By Mariam Sunny and Siddhi Mahatole (Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has ...

GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

This summary provides insights into key developments in the health sector, covering successful Hong Kong listings, animal ...

Alyson Hannigan and Sarah Michelle Gellar were teen actresses together. Now both moms to teens themselves, they’re raising ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.